Previous close | 520.63 |
Open | 520.63 |
Bid | 525.00 |
Ask | 532.65 |
Strike | 250.00 |
Expiry date | 2025-01-17 |
Day's range | 520.63 - 520.63 |
Contract range | N/A |
Volume | |
Open interest | 65 |
Shares of Eli Lilly (LLY) are moving higher on Tuesday morning as the company reported its first-quarter earnings results, revealing a 26% year-over-year revenue increase in a figure of $8.77 billion. Ultimately, this revenue print fell short of estimates ($8.92 billion). The pharmaceutical giant did, however, raise its annual sales forecast by $2 billion due to an insatiable demand for its GLP-1 weight-loss drugs Mounjaro and Zepbound. Yahoo Finance Health Reporter Anjalee Khemlani joins Catalysts to break down the report and what it means for the company moving forward. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Nicholas Jacobino
The latest GLP-1 drugs are starting to see proof of greater use beyond diabetes and obesity. How will it affect makers Novo Nordisk and Eli Lilly?
Tuesday, Eli Lilly And Co (NYSE:LLY) reported first-quarter revenue of $8.77 billion, up 26% year over year, marginally missing the consensus of $8.92 billion, driven by increases of 16% in volume and 10% due to higher realized prices. The volume increase was primarily driven by growth from Mounjaro, Zepbound, Verzenio, and Jardiance, partially offset by declines in Trulicity. Strong demand for the company’s incretin medicines outpaced supply increases. Also Read: Changing Frugal Eating Habits –